Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml
about
Comprehensive assessment for novel prostate cancer markers in the prostate-specific antigen era: focusing on Asians and Asian countriesClinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literatureSerum markers in prostate cancer detectionThe prostate health index selectively identifies clinically significant prostate cancer.Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection BiomarkersIdentification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray AnalysisRNA biomarkers to facilitate the identification of aggressive prostate cancerMulticenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis.Glypican-1 as a Biomarker for Prostate Cancer: Isolation and CharacterizationThe Prostate Health Index: a new test for the detection of prostate cancer.Novel biomarkers for the detection of prostate cancer.Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis.Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen.Current biomarkers for diagnosing of prostate cancer.Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer.Screening and Detection of Prostate Cancer-Review of Literature and Current Perspective.Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.The emerging role of obesity, diet and lipid metabolism in prostate cancer.Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness.The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA iImproving multivariable prostate cancer risk assessment using the Prostate Health Index.Role of PSA density in diagnosis of prostate cancer in obese men.Tissue-based biomarkers in prostate cancer.First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography-guided biopsies for the diagnosis of localised prostate cancer.Is in vitro-acquired resistance to enzalutamide a useful model?Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy
P2860
Q26996461-BC524635-5ECC-42CD-A734-A0402318CBB9Q33911725-728EB17D-A33C-40D4-9A17-1CA7DDE2ADAFQ35042519-BDB8E09F-0103-48BC-B775-E26468F48D12Q35498981-E9A670DE-E149-4265-9FF3-D6523E3FA231Q36123823-0BAA05D2-824A-4B4A-8DB7-F8DEE909D28AQ36150385-097ACC01-3712-47DC-A173-2EBDA928AEEDQ36260364-D8EBA01F-D808-476D-AB99-569ACA857226Q36416441-BB20D941-B930-4C14-874B-34BD92206C1BQ36886346-B3C16FC8-B6B1-430C-B0D7-7473F77A2CBDQ37012083-7A0D1D28-A39B-4B03-B900-5B5E09C9CD27Q37619016-78947601-FA6A-4161-B00B-759357B9A1C6Q37708174-B5D90861-1787-4BC1-B42C-A8930DED2310Q37738370-7DB5D996-CB4A-4964-9942-8F3C700DA898Q38241107-7B746CE3-5EB3-420F-87B2-7902DF37B746Q38584370-6B7D5898-FB42-4DF6-BAF1-FF572678A1BDQ38703676-32A29A5E-312E-41C4-8945-07026A73F5EDQ38762709-25AB2178-6BD8-415F-A4C3-801F816FF36CQ38786630-79666A30-7441-4BC2-97C1-146808091693Q38821546-08854945-84B1-4013-A9ED-5489578E3981Q40211476-442AAB07-808E-4781-BD2A-6C747E6EF002Q40267154-3E2A0E3F-F3F3-4943-B5B2-AB17A67924A9Q40270088-3152B66F-DEC2-4731-AFF2-C1B9F4D6E034Q44302003-ADE68355-9A81-4A5F-BAD9-725D9173F17CQ47144748-8CA1EF3A-A48F-41B8-BAA7-4C40BBD9EB83Q47751279-A64D8280-097F-4476-BC32-167A420E3B7AQ48658920-9D8CE142-B6A0-4A21-876B-B2AC3879D2EAQ57565075-9F14A8DC-66E6-4234-A540-02DFFC0F9AFF
P2860
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Prostate Health Index (Phi) an ...... total PSA range of 2-10 ng/ml
@ast
Prostate Health Index (Phi) an ...... total PSA range of 2-10 ng/ml
@en
Prostate Health Index
@nl
type
label
Prostate Health Index (Phi) an ...... total PSA range of 2-10 ng/ml
@ast
Prostate Health Index (Phi) an ...... total PSA range of 2-10 ng/ml
@en
Prostate Health Index
@nl
prefLabel
Prostate Health Index (Phi) an ...... total PSA range of 2-10 ng/ml
@ast
Prostate Health Index (Phi) an ...... total PSA range of 2-10 ng/ml
@en
Prostate Health Index
@nl
P2093
P2860
P50
P1433
P1476
Prostate Health Index (Phi) an ...... total PSA range of 2-10 ng/ml
@en
P2093
Ada Marino
Claudia Mazzarella
Daniela Terracciano
Gennaro Musi
Giuseppe Di Lorenzo
Giuseppe Perruolo
Sisto Perdonà
Vincenzo Cosimato
Vittoria D'Esposito
P2860
P304
P356
10.1371/JOURNAL.PONE.0067687
P407
P577
2013-07-04T00:00:00Z